{"pmid":32500589,"title":"Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D - Dimer: COVID 19 and Superficial thrombophlebitis.","text":["Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D - Dimer: COVID 19 and Superficial thrombophlebitis.","Dermatol Ther","Demirbas, Abdullah","Elmas, Omer Faruk","Tursen, Umit","Atasoy, Mustafa","Lotti, Torello","32500589"],"journal":"Dermatol Ther","authors":["Demirbas, Abdullah","Elmas, Omer Faruk","Tursen, Umit","Atasoy, Mustafa","Lotti, Torello"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500589","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/dth.13768","keywords":["covid-19","d - dimer","heparin","superficial thrombophlebitis"],"e_drugs":["Heparin"],"topics":["Case Report"],"weight":1,"_version_":1668890966266740736,"score":9.490897,"similar":[{"pmid":32476080,"title":"The association between treatment with heparin and survival in patients with Covid-19.","text":["The association between treatment with heparin and survival in patients with Covid-19.","This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with heparin, hydroxychloroquine, azithromycin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1447 had been discharged home from the hospitals, 201 were still admitted, and 126 had been transferred to hospitals not included in the study. Median follow up time was 8 (IQR 5-12) days. Heparin had been used in 1734 patients. Heparin was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI) 0.55 (0.37-0.82) p = 0.003. This association remained significant when saturation of oxygen < 90%, and temperature > 37 degrees C were added to de model with OR 0.54 (0.36-0.82) p = 0.003, and also when all the other drugs were included as covariates OR 0.42 (0.26-0.66) p < 0.001. The association between heparin and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized controlled trials to assess the causal effects of heparin in different therapeutic regimes are required.","J Thromb Thrombolysis","Ayerbe, Luis","Risco, Carlos","Ayis, Salma","32476080"],"abstract":["This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with heparin, hydroxychloroquine, azithromycin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1447 had been discharged home from the hospitals, 201 were still admitted, and 126 had been transferred to hospitals not included in the study. Median follow up time was 8 (IQR 5-12) days. Heparin had been used in 1734 patients. Heparin was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI) 0.55 (0.37-0.82) p = 0.003. This association remained significant when saturation of oxygen < 90%, and temperature > 37 degrees C were added to de model with OR 0.54 (0.36-0.82) p = 0.003, and also when all the other drugs were included as covariates OR 0.42 (0.26-0.66) p < 0.001. The association between heparin and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized controlled trials to assess the causal effects of heparin in different therapeutic regimes are required."],"journal":"J Thromb Thrombolysis","authors":["Ayerbe, Luis","Risco, Carlos","Ayis, Salma"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476080","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s11239-020-02162-z","keywords":["coronavirus infections","covid-19","heparin","mortality","pulmonary embolism","thrombosis"],"locations":["Spain","heparin","clinicians"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment"],"weight":1,"_version_":1668437835170971648,"score":73.64589},{"pmid":32367558,"title":"Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?","text":["Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?","Recent studies have focused on the comorbid conditions of the COVID-19. According to the current studies, numerous diseases including lung disease, cardiovascular disease, and immunosuppression appear to be at higher risk for severe forms of the COVID-19. To date, there are no data in the literature on the comorbid dermatologic diseases and COVID-19. We tried to analyze the previous dermatological comorbidity of 93 patients with COVID-19 (51 males, 42 females) who presented to the dermatology outpatient clinics for the last 3 years. The most common dermatologic diseases in patients with COVID-19 who have dermatologic diseases for the last three years were superficial fungal infections (24, 25.8%), seborrheic dermatitis (11, 11.8%), actinic keratosis (10, 10.8%), psoriasis (6, 6.5%) and eczema (6, 6.5%), respectively. In addition, the number of COVID-19 patients who presented to dermatology in the last three months was 17 (11 men, 6 women). The median age of these patients was 58 (minimum 18, maximum 80) years, and the most common dermatologic diseases before diagnosed COVID-19 were superficial fungal infections (5, 25%), psoriasis (4, 20%), and viral skin diseases (3, 15%). The possible similarity between cutaneous and mucosal immunity and immunosuppression suggests that patients with some dermatologic diseases especially superficial fungal infections and psoriasis may be more vulnerable to the COVID-19. This article is protected by copyright. All rights reserved.","Dermatol Ther","Kutlu, Omer","Metin, Ahmet","32367558"],"abstract":["Recent studies have focused on the comorbid conditions of the COVID-19. According to the current studies, numerous diseases including lung disease, cardiovascular disease, and immunosuppression appear to be at higher risk for severe forms of the COVID-19. To date, there are no data in the literature on the comorbid dermatologic diseases and COVID-19. We tried to analyze the previous dermatological comorbidity of 93 patients with COVID-19 (51 males, 42 females) who presented to the dermatology outpatient clinics for the last 3 years. The most common dermatologic diseases in patients with COVID-19 who have dermatologic diseases for the last three years were superficial fungal infections (24, 25.8%), seborrheic dermatitis (11, 11.8%), actinic keratosis (10, 10.8%), psoriasis (6, 6.5%) and eczema (6, 6.5%), respectively. In addition, the number of COVID-19 patients who presented to dermatology in the last three months was 17 (11 men, 6 women). The median age of these patients was 58 (minimum 18, maximum 80) years, and the most common dermatologic diseases before diagnosed COVID-19 were superficial fungal infections (5, 25%), psoriasis (4, 20%), and viral skin diseases (3, 15%). The possible similarity between cutaneous and mucosal immunity and immunosuppression suggests that patients with some dermatologic diseases especially superficial fungal infections and psoriasis may be more vulnerable to the COVID-19. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Kutlu, Omer","Metin, Ahmet"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367558","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dth.13509","keywords":["covid-19","sars-cov-2","dermatology","immunosuppression","psoriasis","superficial fungal infections"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496265355265,"score":69.20218},{"pmid":32445064,"title":"Heparin resistance in COVID-19 patients in the intensive care unit.","text":["Heparin resistance in COVID-19 patients in the intensive care unit.","Patients with COVID-19 have a coagulopathy and high thrombotic risk. In a cohort of 69 intensive care unit (ICU) patients we investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation. 15 of the patients have received therapeutic anticoagulation with either unfractionated heparin (UFH) or low molecular weight heparin (LMWH), of which full information was available on 14 patients. Heparin resistance to UFH was documented in 8/10 (80%) patients and sub-optimal peak anti-Xa following therapeutic LMWH in 5/5 (100%) patients where this was measured (some patients received both anticoagulants sequentially). Spiking plasma from 12 COVID-19 ICU patient samples demonstrated decreased in-vitro recovery of anti-Xa compared to normal pooled plasma. In conclusion, we have found evidence of heparin resistance in critically unwell COVID-19 patients. Further studies investigating this are required to determine the optimal thromboprophylaxis in COVID-19 and management of thrombotic episodes.","J Thromb Thrombolysis","White, D","MacDonald, S","Bull, T","Hayman, M","de Monteverde-Robb, R","Sapsford, D","Lavinio, A","Varley, J","Johnston, A","Besser, M","Thomas, W","32445064"],"abstract":["Patients with COVID-19 have a coagulopathy and high thrombotic risk. In a cohort of 69 intensive care unit (ICU) patients we investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation. 15 of the patients have received therapeutic anticoagulation with either unfractionated heparin (UFH) or low molecular weight heparin (LMWH), of which full information was available on 14 patients. Heparin resistance to UFH was documented in 8/10 (80%) patients and sub-optimal peak anti-Xa following therapeutic LMWH in 5/5 (100%) patients where this was measured (some patients received both anticoagulants sequentially). Spiking plasma from 12 COVID-19 ICU patient samples demonstrated decreased in-vitro recovery of anti-Xa compared to normal pooled plasma. In conclusion, we have found evidence of heparin resistance in critically unwell COVID-19 patients. Further studies investigating this are required to determine the optimal thromboprophylaxis in COVID-19 and management of thrombotic episodes."],"journal":"J Thromb Thrombolysis","authors":["White, D","MacDonald, S","Bull, T","Hayman, M","de Monteverde-Robb, R","Sapsford, D","Lavinio, A","Varley, J","Johnston, A","Besser, M","Thomas, W"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445064","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11239-020-02145-0","keywords":["covid-19","heparin","intensive care","thrombosis"],"locations":["optimal","thromboprophylaxis"],"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1667600475927609344,"score":66.92238},{"pmid":32378044,"pmcid":"PMC7201114","title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","text":["Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","Intern Emerg Med","Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca","32378044"],"journal":"Intern Emerg Med","authors":["Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378044","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s11739-020-02358-4","keywords":["covid-19","heparin","treatment"],"e_drugs":["Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666262687609257984,"score":63.096542},{"pmid":32399449,"pmcid":"PMC7213837","title":"Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?","text":["Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?","Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we describe two patients with COVID-19 pneumonia who developed venous thromboembolism. LEARNING POINTS: Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia.Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia.In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, irrespective of disease stage.","Eur J Case Rep Intern Med","Poggiali, Erika","Bastoni, Davide","Ioannilli, Eva","Vercelli, Andrea","Magnacavallo, Andrea","32399449"],"abstract":["Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we describe two patients with COVID-19 pneumonia who developed venous thromboembolism. LEARNING POINTS: Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia.Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia.In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, irrespective of disease stage."],"journal":"Eur J Case Rep Intern Med","authors":["Poggiali, Erika","Bastoni, Davide","Ioannilli, Eva","Vercelli, Andrea","Magnacavallo, Andrea"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399449","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.12890/2020_001646","keywords":["covid-19 pneumonia","deep vein thrombosis","heparin","pulmonary embolism","venous thromboembolism"],"locations":["Pneumonia"],"e_drugs":["Heparin"],"topics":["Case Report"],"weight":1,"_version_":1666714494762483713,"score":55.058395}]}